Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 weeks then every two weeks.

Trial Details

NCT ID
NCT07314294
Phase
PHASE2
Sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • EMB-01 1600 mg administered once weekly throughout the study
  • EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Able to understand and willing to sign the informed consent form (ICF).
  • Male or female aged ≥ 18 years.
  • Histologically or cytologically confirmed unresectable or metastatic left-sided colorectal cancer (primary tumor from splenic flexure to rectum) wi…
  • ECOG performance status ≤ 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →